Related Experiment Video
Updated: Aug 26, 2026

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation
Published on: March 14, 2017
Molecular mechanisms of primary hyperparathyroidism
1Departments of Medicine, Physiology and Human Genetics, McGill University, Calcium Research Laboratory, Royal Victoria Hospital, Montreal, Quebec, Canada. gnhendy@med.mcgill.ca
Abstract:
Several advances have been achieved toward the goal of understanding the molecular basis of parathyroid tumorigenesis. The cyclin D1/PRAD1 oncogene has been identified, and is involved in the development of several different tumor types besides those of the parathyroid. The tumor suppressor RB gene has been linked to the pathogenesis of parathyroid carcinoma. The MEN-1 gene product has been identified and mutations in MENIN shown to contribute to sporadic tumors. An understanding of the functions of MENIN will provide further insights into parathyroid disease. Mutations in the RET gene have been identified as the causal agent in MEN-2 but this gene contributes rarely to development of sporadic parathyroid tumors. Ultimately, a description of parathyroid tumorigenesis will need to account for such features as the rarity of parathyroid carcinoma, the increased incidence of tumors after neck irradiation, and the increased frequency of hyperparathyroidism in postmenopausal women. In addition, the relationship between excessive cellular proliferation and an altered set-point in the mechanism linking extracellular calcium concentration to PTH secretion requires explanation. While mutations in the CASR gene itself play a critical role in familial disease, they do not appear to be involved in sporadic parathyroid tumorigenesis, and investigation of genes important for its expression is clearly warranted.
Insights
Advances in understanding parathyroid tumors reveal key genes like cyclin D1 and MENIN. Further research is needed to explain tumor rarity and calcium-sensing mechanisms in parathyroid disease.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Parathyroid tumorigenesis involves complex molecular mechanisms.
- Several genetic factors have been implicated in parathyroid tumor development.
Purpose of the Study:
- To review recent advances in understanding the molecular basis of parathyroid tumorigenesis.
- To identify key genes and pathways involved in parathyroid tumor development and pathogenesis.
Main Methods:
- Literature review of genetic mutations and their roles in parathyroid tumors.
- Analysis of oncogenes, tumor suppressor genes, and their involvement in parathyroid pathogenesis.
Main Results:
- Cyclin D1/PRAD1 oncogene identified in various tumors, including parathyroid.
- RB gene linked to parathyroid carcinoma; MEN-1 gene mutations found in sporadic tumors.
- RET gene mutations are causal in MEN-2 but rare in sporadic parathyroid tumors; CASR gene mutations are critical in familial but not sporadic disease.
Conclusions:
- Understanding MENIN function is crucial for insights into parathyroid disease.
- Future research should focus on genes regulating CASR expression for sporadic parathyroid tumorigenesis.
- A comprehensive model of parathyroid tumorigenesis must explain tumor rarity, environmental factors, and calcium-sensing alterations.
Related Concept Videos
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
The Parathyroid Glands
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by producing...
Hyperthyroidism I: Introduction
Hyperthyroidism II: Pathophysiology
Graves Disease II: Pathophysiology
Hypothyroidism II: Pathophysiology

